Taiho Oncology, Inc.
Helen Helen has a strong background in biostatistics and programming. Helen started their career as a Senior Biostatistician at the University of Toronto/University Health Network, where they worked from 1998 to 2006. Helen then joined Bristol Myers Squibb as an Associate Director Biometrics and remained there until 2016. In 2016, they joined Eisai US as a Director of Biostatistics and Programming before moving to their current role as the Vice President Head of Biostatistics/Programming/Data Management at Taiho Oncology, Inc. Their extensive experience and leadership roles make their well-suited for their current position.
Helen He's education history includes a PhD in Biostatistics from the University of Toronto and an MD in Medicine from Zhejiang University and Zhejiang Medical University. The specific start and end years for both degrees are not provided.
This person is not in any offices
Taiho Oncology, Inc.
2 followers
The mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in the development of orally administered anti-cancer agents and markets these medicines for a range of tumor types in the U.S. Taiho Oncology’s growing pipeline of selectively targeted anti-cancer agents is led by a world-class clinical development organization. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company’s European and Canadian operations, which are located in Zug, Switzerland and Oakville, Ontario, Canada. For more information, visit www.taihooncology.com